drugset / Trial / NCT05883449
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
RandomizedSequentialOpen-labelTreatment
Summary
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Timeline
- Start
- 2023-10-10
- Primary completion
- 2024-11-07
- Completion
- 2025-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB-101 | Cell therapy | 2e+09 cells | Intravenous |
| Subject | AB-101 | Cell therapy | 4e+09 cells | Intravenous |
| Subject | ACIMTAMIG | Protein / enzyme biologic | 200 mg | Intravenous |
| Subject | ACIMTAMIG | Protein / enzyme biologic | 300 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |